UPDATE : Monday, February 17, 2020
상단여백
JW Pharmaceutical’s hyperlipidemia drug Livalo safe from diabetes risk by Jeong Sae-im 2019-08-30 14:49
Change in licensing-out contract may be bad sign for Intron Biotechnology by Jeong Sae-im 2019-08-30 14:47
Antidiabetic DPP-4 inhibitors mark double-digit sales growth by Jeong Sae-im 2019-08-29 11:24
Sales of new gastric acid blocker K-Cab top ₩10 billion by Jeong Sae-im 2019-08-28 13:26
Invossa victims, Kolon shareholders demand apology, compensation by Jeong Sae-im 2019-08-27 15:40
라인
HLB to test rivoceranib+Lonsurf in colon cancer by Jeong Sae-im 2019-08-27 15:39
Regulator decides to delist Kolon TissueGene by Jeong Sae-im 2019-08-27 12:15
Pharmaceutical sector’s job growth twice of all industries’ average by Jeong Sae-im 2019-08-26 11:39
HLB wins FDA nod for P2 trial on rivoceranib in adenoid cystic carcinoma by Jeong Sae-im 2019-08-23 15:02
GenNBio to test transplanting pig’s pancreatic islet into human next year by Jeong Sae-im 2019-08-23 13:53
라인
Medical device makers to fight bias against homemade products by Jeong Sae-im 2019-08-20 12:50
Medipost’s stem cell therapy, cord blood bank show solid growth by Jeong Sae-im 2019-08-16 16:18
Korean firms eyeing on growing orphan drug market by Jeong Sae-im 2019-08-14 14:48
‘Koreans don’t recognize suicidal signals well’ by Jeong Sae-im 2019-08-13 11:14
‘CPhI Korea thriving on local firms’ zeal for drug export’ by Jeong Sae-im 2019-08-08 14:54
라인
[Reporter’s Notebook] SillaJen should be ashamed of itself by Jeong Sae-im 2019-08-07 13:59
HLB to seek pre-NDA meeting with FDA for rivoceranib by Jeong Sae-im 2019-08-06 15:43
SillaJen remains confident about Pexa-Vec’s value, despite trial failure by Jeong Sae-im 2019-08-05 14:49
Suspicions resurge over SillaJen execs’ stock selling before Pexa-Vec trial suspension by Jeong Sae-im 2019-08-05 11:26
Biotech shares tank amid SillaJen’s likely halt of Pexa-Vec trial by Jeong Sae-im 2019-08-02 15:45
여백
여백
여백
Back to Top